TABLE 1. Requirements for Gene Therapy
Eficient transduction system Stable, high-level expression of gene product Tissue-specific expression system Minimal risk of mutagenesis and persistent infection of the recipient transfection efficiencies of 0.1-l % . 4 9 5 Retroviral vectors transduce primarily dividing cells and integrate into host chromosome in a random manner. These vectors may not be suitable to express genes in postmitotic cells, such as cardiac myocytes. Previous studies have shown that retroviral infection can be inhibited in replicating cells and culture, and that such infected cells must be replicating at the time of infection for successful gene transfer.6 A potential complication of retroviral infection is recombination to a wild-type virus which could replicate in an uncontrolled manner in the host organism. To minimize this potential complication, viral gene products required for replication are deleted from the retroviral sequence and introduced into packaging cell When the retrovirus is cotransfected in packaging cell lines, a viral particle capable of infection is produced; however, the virion cannot replicate. This reduces the possibility that the retrovirus will duplicate after introduction into the host ceL9 Retroviral gene transfer has been performed directly in pig arteries without detection of helper-virus activity up to five months after tran~duction,~ suggesting that this vector is relatively safe.
Transfection employing cationic liposomes has been commonly used to achieve high efficiency in cultured cells. Development of commercialized forms of cationic liposomes in the late 1980s resulted in their broad use for in vitro and in vivo transfection.10 Cationic lipid vesicles condense with DNA to form complexes in which the DNA is trapped." Because virtually all biological surfaces have a net negative charge, the positively charged lipid vesicles containing polynucleotide interact spontaneously with these surfaces, delivering polynucleotide to the cell. Cationic lipid/polynucleotides fuse with cell membranes in such a manner that the entrapped DNA avoids degradation in the liposomal component.I2 After delivery to the cytoplasm, plasmid DNA translocates to the nucleus and persists in the nucleus predominantly as an episome. Integration into host chromosome occurs at a low frequency. Transient expression levels and stable transformation efficiencies depend upon the expression vector and cell lines.13 Several technical factors are also important in cationic liposome transfection including the ratio of liposome to DNA, the cationic liposome formulation, and the use of serumfree conditions. The advantages of cationic liposome transfection include safety, reproducibility, and ease of preparation. Safety concerns about the use of retrovirus or adenovirus in humans are largely mitigated by this nonviral vector.
Recombinant adenoviruses have several properties that make them attractive vectors for in vivo gene delivery, including high-efficiency gene transfer. Several studies have reported in vivo gene delivery using adenovirus into vascular cells with efficiencies of >50% of vascular cells.14 This high efficiency results from effective propagation of adenoviral stocks to high titer, the promiscuity and tissue trophism of adenoviral infection of cells, and the infectivity of adenovirus for replicating and nonreplicating cells. l5 In dividing cells, adenoviral sequences integrated low frequency into host chromosomes. However, in nondividing somatic cells in vivo, the adenoviral genome appears to be maintained as an episome.16 Several issues relevant to the application of adenoviral vectors to human therapies are currently being investigated, including stability of gene expression, host-cell immune responses, transmission to germ-line cells, and toxicity.
GENE TRANSFER INTO VASCULAR CELLS
For several years, we have been interested in developing gene transfer to directly introduce new genes into vascular cells in vivo in order to study the pathophysiology of vascular disease. In particular, we have been interested in investigating the mechanisms of cellular proliferation in arteries after expression of growth factor and cytokine genes in arteries in vivo. A variety of growth factors have been reported to stimulate vascular cell proliferation and vessel formation in vivo. [17] [18] [19] [20] Although the genes encoding many factors have been cloned and their mechanism of action defined in vitro, definition of their role in vivo has been more difficult to analyze. To address this question we introduced recombinant genes for three growth factors, PDGF B, secreted FGF-1 (acidic FGF), and active TGF-P1, into pig arteries in vivo using gene transfer (TABLE 2). The advantage of this system is that a recombinant growth factor gene can be transfected into a local artery segment where its expression and effects on arterial function can be e~a l u a t e d .~.~' PDGF BB is a potent smooth muscle cell mitogen and smooth muscle chemoattractant. 22.23 The function of the PDGF B gene in tissue injury and restenosis in vivo has been more difficult to address. To investigate the in vivo function of a PDGF B gene, we transfected a plasmid expression vector encoding a human PDGF B gene into porcine arteries.24 Transfer of plasma DNA was documented by PCR; an expression of mRNA was confirmed by reverse transcriptase PCR. Recombinant PDGF BB protein was detected in transduced arteries by immunohistochemistry using a monoclonal antibody against human PDGF BB. Porcine arteries transduced with PDGF BB demonstrated severe intimal thickening, characterized by increased cellularity and smooth muscle cell proliferation in contrast to control arteries transduced with a reporter gene. Quantitative morphometry confirmed a significant difference in intimal-to-medial ratio between PDGF B and control arteries. Further studies are investigating the mechanisms of PDGF B-induced intimal hyperplasia, including proliferation kinetics.
The heparin binding fibroblast growth factor family has proliferative and angiogenic properties in ~i v o .~' . '~ To investigate the role of FGF-1 in vascular pathology, we transfected a plasmid expression vector encoding for secreted FGF-1 into In more recent studies, the role of TGF-pl in normal arteries has been explored after transfection of a plasmid expression vector encoding an active form of TGFpl into normal porcine arteries. In these studies,28 we found that TGF-p1 is associated with increased procollagen and collagen synthesis in the media and intima of TGF-PI-transfected arteries, in contrast to control arteries transfected with a reporter gene.
Findings from these experiments which have examined the in vivo function of three growth factor genes suggest that expression of a recombinant growth factor gene can have direct and indirect effects on vascular function in vivo. For example, expression of PDGF BB is associated with intense intimal cellular proliferation, and FGF-1 may play a role in stimulating vascular angiogenesis, whereas TGFpl is associated with increased extracellular matrix production. Despite these different patterns of gene expression, all three growth factor genes produced some intimal thickening. These findings suggest that intimal thickening may represent a common response to gene expression of multiple growth factors that each in turn exert distinct effects on vessel repair. On the basis of these studies examining the function of growth factor genes in vivo, animal models of vascular disease can be developed and molecular targets can be tested.
SUMMARY
Several issues are important to the use of direct gene transfer as an investigative tool and as a potential therapeutic modality (TABLE 3) . Transfection efficiencies of different vectors must be improved and optimized. Retroviral vectors and DNA liposome conjugates currently used in animal models are low-efficiency vectors. Adenoviruses and adenoviral conjugates appear promising, but issues related to gene persistence, germ-line transmission, and stability of expression must be explored. Second, the pharmacology or dose-response properties of recombinant gene expression have not been investigated. It is not currently known how many cells must be transfected in an arterial segment in order to produce a desired biological effect. Our studies suggest that only a small population of cells is required to secrete a recombinant gene product into the local milieu. This gene product may then have local paracrine effects with amplification of the biological response, suggesting a "gain of function." Third, methods must be developed to target recombinant genes specifically to endothelial cells or smooth muscle cells using cell-specific promoters. Finally, gene expression should be regulated through inducible or repressible promoters.
Nonetheless, during the past ten years a dramatic expansion in the fields of gene transfer and gene therapy has occurred. We have entered a new era in which molecular genetic techniques are being increasingly used to investigate the pathophysiology of cardiovascular disorders and to design potential therapies for these diseases. Although technical hurdles related to optimization of vectors and regulated gene expression must be solved, molecular genetic approaches will be increasingly used to study and treat cardiovascular diseases.
